Status:
NOT_YET_RECRUITING
CT Volume Measurement of Hepatocellular Carcinoma
Lead Sponsor:
Assiut University
Conditions:
Hepatocellular Carcinoma (HCC)
CT
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to evaluate the role of CT volumetric measurement in assessing treatment response of hepatocellular carcinoma (HCC) following trans arterial chemoembolization (TACE) or microw...
Detailed Description
Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer and a major contributor to cancer-related mortality worldwide (1). Conventional curative interventions for HCC encompass ...
Eligibility Criteria
Inclusion
- Adult patients (≥18 years) with a confirmed diagnosis of HCC based on AASLD or EASL criteria.
- Patients deemed unresectable by the multidisciplinary tumor board.
- Patients scheduled for TACE as the primary locoregional therapy.
- Preserved liver function (Child-Pugh class A or B).
- Adequate renal function to permit contrast-enhanced CT.
Exclusion
- Patients with extrahepatic metastases or portal vein thrombosis.
- Patients with contraindications to iodinated contrast or TACE.
- Patients with severe comorbid illness that precludes participation.
- Patients refuse to provide informed consent.
Key Trial Info
Start Date :
October 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2027
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT07183566
Start Date
October 1 2025
End Date
November 1 2027
Last Update
September 19 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.